Table 1 Representation of primary and secondary outcomes, their labels and timepoints of administration
Outcome | Measure label | Measure timepoints |
|---|---|---|
Primary outcome | ||
 Feasibility and acceptability | Participant satisfaction survey | At Week 8 |
Attendance sheet | After each session | |
Exit questionnaire | Following disengagement with intervention | |
Focus group | At Week 9 | |
Secondary outcomes | ||
 Substance use  (a) Days of primary substance used  (b) Usage of primary substance per day  Physical Wellbeing  Mental Wellbeing  Overall Quality of Life | Treatment Outcome Profile (TOP) | Baseline and Week 8 (end of treatment) |
 Retention in treatment completion rate | WDP Case management system | At week 11 |
 Substance craving | Brief Substance Craving Scale (BSCS) | Baseline and week 8 (end of treatment) |
 Neural correlates of substance craving | Beta frequency band/resting state | Baseline and week 8 (end of treatment) |
 Levels of depressive symptoms | Patient Health Questionnaire–9 (PHQ-9) | Baseline and week 8 (end of treatment) |
 Neural correlates of depressive symptoms | FAA/resting state | Baseline and week 8 (end of treatment) |
 Levels of anxiety | Generalised Anxiety Disorder–7 (GAD–7) | Baseline and week 8 (end of treatment) |
 Neural correlates of anxiety symptoms | FMT/resting state | Baseline and week 8 (end of treatment) |
 Inhibitory control | Visual behavioral Go/No-Go task | Baseline and week 8 (end of treatment) |
 Neural correlates of inhibitory control | EEG event-related potential (ERP) P3 | Baseline and week 8 (end of treatment) |
 Therapeutic alliance | The Helping Alliance Questionnaire–II | After IMT session 2 and 5 |
 Moments of therapeutic interest | Semi-structured Interview | After IMT session 2 and 5 |
Audio-visual data | During IMT session 2 and 5 | |